Peijia Medical 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yi Zhang

최고 경영자

CN¥1.5m

총 보상

CEO 급여 비율	50.7%
CEO 임기	12.5yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Yi Zhang 의 보수는 Peijia Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥252m
Mar 31 2024	n/a	n/a	-CN¥322m
Dec 31 2023	CN¥1m	CN¥740k	-CN¥393m
Sep 30 2023	n/a	n/a	-CN¥460m
Jun 30 2023	n/a	n/a	-CN¥528m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥1m	CN¥1m	-CN¥408m
Sep 30 2022	n/a	n/a	-CN¥449m
Jun 30 2022	n/a	n/a	-CN¥491m
Mar 31 2022	n/a	n/a	-CN¥533m
Dec 31 2021	CN¥2m	CN¥1m	-CN¥574m

보상 대 시장: Yi 의 총 보상 ($USD 201.50K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.03M ).

보상과 수익: 회사가 수익성이 없는 동안 Yi 의 보상이 증가했습니다.

CEO

Yi Zhang (56 yo)

12.5yrs

테뉴어

CN¥1,460,000

보상

Dr. Yi Zhang has been an Executive Director of Peijia Medical Limited since May 30, 2012. He serves as the Chairman and Chief Executive Officer at Peijia Medical Limited and served as its Chief Technology...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yi Zhang	Chairman & CEO	no data	CN¥1.46m	0.80% € 2.5m
Lieh Tsai	Chief Financial Officer	5.6yrs	데이터 없음	데이터 없음
Kongrong Pan	Chief Operating Officer	7.3yrs	데이터 없음	데이터 없음
Fong Tan Jian	Chief Technology Officer	3.8yrs	데이터 없음	데이터 없음
Ping Ye Zhang	Executive Director	4.8yrs	CN¥182.00k	0.16% € 488.9k
Hong Ye	Executive Director & Company Secretary	12.1yrs	CN¥1.36m	2.09% € 6.5m
Xiaoxiao Zhuang	Vice President of Sales	4.6yrs	데이터 없음	데이터 없음
Hongpeng Wang	Vice President of Marketing	5.3yrs	데이터 없음	데이터 없음
Hing Ling Chau	Company Secretary	2.4yrs	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 4WO 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yi Zhang	Chairman & CEO	12.5yrs	CN¥1.46m	0.80% € 2.5m
Ping Ye Zhang	Executive Director	6.3yrs	CN¥182.00k	0.16% € 488.9k
Hong Ye	Executive Director & Company Secretary	12.1yrs	CN¥1.36m	2.09% € 6.5m
Stephen Newman Oesterle	Independent Non-Executive Director	4.8yrs	CN¥1.55m	데이터 없음
Huacheng Wei	Independent Non-Executive Director	3.2yrs	CN¥315.00k	데이터 없음
Wai Ming Yip	Independent Non-Executive Director	4.8yrs	CN¥314.00k	데이터 없음
Fei Chen	Non-Executive Director	5.4yrs	데이터 없음	데이터 없음
Robert Parks	Independent Non-Executive Director	4.8yrs	CN¥1.55m	데이터 없음
Jifeng Guan	Non-Executive Director	5.1yrs	데이터 없음	데이터 없음
Jun Yang	Non-Executive Director	4.3yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 4WO 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Peijia Medical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Less than half of directors are independent

Executive Director & Company Secretary recently sold €362k worth of stock

Less than half of directors are independent

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

New major risk - Share price stability

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

New minor risk - Share price stability

Executive Director & Company Secretary recently sold €362k worth of stock

Forecast to breakeven in 2025

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings released: CN¥0.87 loss per share (vs CN¥4.43 loss in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

New 90-day high: €3.20

New 90-day low: €2.34

New 90-day low: €2.60

Peijia Medical Limited Announces Completion of Patient Enrollment for the Clinical Trial of Tauruselite

Peijia Medical Limited to Report First Half, 2020 Results on Aug 28, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령